Mogle J, Hill NL, Bell TR, Bhargava S, Bratlee-Whitaker E. The factor structure of items assessing subjective memory: between-persons and within-persons across time. Gerontology. 2021;67(3):357-64. doi: 10.1159/000513728
Mogle J, Hill NL, Bell TR, Bhargava S, Bratlee-Whitaker E. The factor structure of items assessing subjective memory: between persons and within-persons across time. Gerontology. 2021 Jan;67(3):357-64. doi: 10.1159/000513728
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Danysh HE, Gilman RH, Wells JC, Pan WK, Zaitchik B, Gonzalvez G, Alvarez M, Checkley W. El Niño adversely affected childhood stature and lean mass in northern Peru. Climate Change Responses. 2014;1(7). doi: 10.1186/s40665-014-0007-z
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.